Henoch-Schönlein Purpura (HSP) Clinical Summary
Diagnosis
Your patient's presentation of joint pain and purpuric rash is highly suggestive of Henoch-Schönlein Purpura, an IgA-mediated systemic small-vessel vasculitis that requires confirmation through specific clinical criteria and consideration of skin biopsy for definitive diagnosis. 1, 2
Diagnostic Criteria
- Palpable purpura (non-thrombocytopenic) is the hallmark finding, typically appearing on lower extremities and buttocks 3, 4, 2
- Diagnosis requires purpura PLUS at least one of the following 2:
- Diffuse abdominal pain
- Arthritis or arthralgia (present in your patient)
- Renal involvement (hematuria and/or proteinuria)
- Biopsy showing predominant IgA deposition
Essential Diagnostic Workup
- Skin biopsy with immunofluorescence should be performed to confirm IgA deposits in vessel walls, as this is sine qua non for diagnosis and prevents both missed diagnoses and unnecessary follow-up 1
- Urinalysis with microscopy to detect hematuria, proteinuria, and red blood cell casts 3, 2
- Serum creatinine and BUN to assess renal function 3
- Serum IgA levels (often elevated) 5
- Fecal occult blood test to screen for gastrointestinal involvement 3, 5
- Complete blood count to confirm normal platelet count (distinguishes from thrombocytopenic purpura) 4
Clinical Manifestations to Monitor
Organ System Involvement
- Skin: Non-blanching purpuric rash on lower extremities and buttocks (100% of cases) 3, 4, 2
- Joints: Migratory polyarthralgias or arthritis, typically affecting knees and ankles 3, 4, 2
- Gastrointestinal: Colicky abdominal pain, which can precede rash; risk of intussusception, bleeding from terminal ileum, or Meckel's diverticulum 3, 5, 4
- Renal: Hematuria and proteinuria; up to 20% develop chronic renal failure after 20 years, with highest risk (>50%) when presenting with combined nephrotic-nephritic syndrome 1, 2
Rare but Serious Complications
- Cardiac: Arrhythmias including atrial fibrillation and non-sustained ventricular tachycardia from cardiac vasculitis 3
- Neurological: Proximal muscle weakness, tremors, and clonus 3
- Renal: Crescentic glomerulonephritis requiring aggressive immunosuppression 3
Management Approach
Mild Disease (Rash and Arthralgia Only)
- Supportive care is the mainstay, as most cases are self-limited with average duration of 4 weeks 2
- Acetaminophen for joint pain 6, 7
- NSAIDs (naproxen 500 mg twice daily or meloxicam 7.5-15 mg daily) for 4-6 weeks if no contraindications 7
- Rest and elevation of affected extremities 2
Moderate Disease (Severe GI Pain or GI Hemorrhage)
- Oral corticosteroids (prednisone 10-20 mg daily or 0.5-1 mg/kg for severe symptoms) should be considered for severe gastrointestinal pain and hemorrhage 7, 2
- Current evidence does NOT support universal corticosteroid treatment for all HSP patients 2
- Early steroid treatment does NOT reduce incidence or severity of nephropathy 2
Severe Renal Involvement
- For severe nephritis or proteinuria persisting >3 months, add ACE inhibitor or angiotensin receptor blocker to corticosteroids to prevent secondary glomerular injury 2
- IV cyclophosphamide for crescentic glomerulonephritis with >75% glomerular involvement 3
- Serial monitoring of renal function every 4-6 weeks 7
Critical Monitoring Requirements
Short-Term (First 4 Weeks)
- Monitor for gastrointestinal complications: Severe abdominal pain may indicate intussusception or GI bleeding requiring urgent endoscopy 3, 4
- Serial urinalysis to detect new-onset or worsening renal involvement 2
- Blood pressure monitoring for hypertension 2
Long-Term Follow-Up
- Renal surveillance is mandatory even after apparent complete recovery, as renal signs can manifest years after initial presentation 1, 2
- Urinalysis and blood pressure checks at 1,3,6, and 12 months, then annually for at least 5 years 2
- Risk of chronic renal failure persists even with mild initial renal symptoms 1
Prognosis
Most cases have excellent outcomes with complete resolution, but renal involvement is the most important prognostic factor determining long-term morbidity and mortality 2. The disease is more severe in adolescents compared to younger children, requiring closer monitoring for systemic complications 3.